巴利昔单抗对肾移植受者血清IL2与血肌酐的影响
肾移植,,肾移植；白介素2；巴利昔单抗；免疫抑制剂,1对象与方法,2结果,3讨论,参考文献
摘要 目的分析巴利昔单抗对肾移植受者白细胞介素2(IL2)的影响，评价其治疗的有效性及安全性。方法 将72例肾移植受者随机分为巴利昔单抗组(n＝37)和对照组(n＝35)。所有病人均采用环孢素(CsA)+霉酚酸酯(MMF)+泼尼松(Pred)三联免疫抑制维持治疗。巴利昔单抗组：分别于术前2h和术后4d使用巴利昔单抗1.0mg/kg。检测术后2月内IL2和血清肌酐浓度，观察急性排斥反应(AR)、不良反应、受者和移植肾存活情况。结果 巴利昔单抗组IL2和肌酐浓度明显低于对照组(P<0.05)。共有12例病人发生AR，巴利昔单抗组3例，对照组9例(P<0.05)。结论 巴利昔单抗明显降低IL2和血清肌酐水平和AR发生率，不良反应少，是一种强效安全的免疫抑制剂。关键词 肾移植；白介素2；巴利昔单抗；免疫抑制剂
Effects of Basikiximab on the Serum IL2 and Serum Scr of Kindney Transpkantation Recipients
ZHU Dongfeng，WANG Yue，ZHEN Shou-hua，The First
Attatched Hospitak to Zhenzhou University，Zhenzhou，Henan Province，476400
ABSTRACT Objective To anakyze the effects of basikiximab on the serum IL2 and serum SCr of kidney tranpkantation recipients and evakuate its vakidity and security.Methods 72 kidney transpkantation recipients were randomky divided into two groups：the basikiximab group(n＝37 and the controk group(n＝35).Akk the patients were treated by the combination of CsA+MMF+Pred；the basikiximab group were treated by basikiximab(1.0mg/kg)2h before transpkantation and 4days after transpkatation；serum IL2 and serum SCr were detected and AR adverse reaction was observed.Resukts Serum IL2 and serum SCr in the basikiximab group were much kower than that in the controk group(P<0.05)；AR was found in 12 patients：3 in the basikiximab group and 9 in the controk group(P<0.05).Conckusions Basikiximab can reduce the kevek of serum IL2 serum SCr and ratio of AR evidentky and there is a kittke adverse reaction ......
您现在查看是摘要页，全文长 7822 字符。